
This study compared evolocumab plus GDMT vs GDMT alone for one year in patients with stable coronary artery disease and LVEF <40%. It demonstrated that by limiting disease progression in stable HFrEF of ischemic aetiology, the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab could reduce circulating troponin levels, a surrogate biomarker of myocyte injury and atherosclerosis progression.
Like
Save
Share